Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
Previous Symbol
CUSIPN/A
Phone626-304-3400
Debt
Debt-to-Equity Ratio0.02
Current Ratio8.69
Quick Ratio8.69
Price-To-Earnings
Trailing P/E Ratio-27.43
Forward P/E Ratio-18.68
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.41 million
Price / Sales36.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.08 per share
Price / Book11.94
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-34,380,000.00
Net Margins-400.13%
Return on Equity-59.39%
Return on Assets-50.38%
Miscellaneous
Employees93
Outstanding Shares88,020,000
Market Cap$1.16 billion
OptionableOptionable
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) posted its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company earned $0.73 million during the quarter, compared to the consensus estimate of $0.62 million. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. View Arrowhead Pharmaceuticals' Earnings History.
When is Arrowhead Pharmaceuticals' next earnings date?
What price target have analysts set for ARWR?
6 equities research analysts have issued 12-month price targets for Arrowhead Pharmaceuticals' stock. Their predictions range from $11.68 to $25.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $21.4467 in the next twelve months. This suggests a possible upside of 66.4% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.
What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.
What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $24 PT on Arrowhead Pharmaceuticals, following release of late-breaker abstracts for the Liver Meeting (AASLD) being held on San Francisco. Additional data from Arrowhead’s lead programs in hepatitis B virus (HBV) and alpha-1 antitrypsin (AAT) were made available further supporting activity of both compounds in chronic HBV patients and healthy volunteers, respectively. We believe these initial data add readthrough going into the meeting and further underscore Arrowhead’s ability to establish a platform RNAi company." (10/11/2018)
- 2. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
Media coverage about ARWR stock has been trending very positive on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a news sentiment score of 3.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH), Emergent Biosolutions (EBS), Horizon Pharma (HZNP), Array Biopharma (ARRY), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Akcea Therapeutics (AKCA) and Ascendis Pharma A/S (ASND).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
- Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
- Dr. Bruce D. Given, Chief Operating Officer (Age 64)
- Mr. Patrick O'Brien, Gen. Counsel (Age 54)
- Mr. Peter B. Leone MBA, VP of Strategic Bus. Initiatives (Age 61)
Who are Arrowhead Pharmaceuticals' major shareholders?
Arrowhead Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include OppenheimerFunds Inc. (8.87%), BlackRock Inc. (8.06%), First Manhattan Co. (5.74%), Vanguard Group Inc. (4.49%), Vivo Capital LLC (2.65%) and FMR LLC (2.25%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski and Peter Brian Leone. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?
ARWR stock was sold by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., Morgan Stanley, Virtus ETF Advisers LLC, AQR Capital Management LLC, TIAA CREF Investment Management LLC, ClariVest Asset Management LLC, Rhumbline Advisers and OppenheimerFunds Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski and Peter Brian Leone. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?
ARWR stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, First Manhattan Co., Candriam Luxembourg S.C.A., Vivo Capital LLC, Oak Ridge Investments LLC, Baker BROS. Advisors LP, EAM Investors LLC and Sio Capital Management LLC. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $12.89.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $1.16 billion and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.
What is Arrowhead Pharmaceuticals' official website?
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
